SCHEMBL2484841

SCHEMBL2484841

O=C(OCc1ccccc1)Oc1cc2cc(Cl)ccc2n1C(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 4/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
P2RX4 Q99571 2/20 0.39
HTT P42858 1/20 0.39
GFER P55789 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 1/20 0.39
OGT O15294 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
EGFR P00533 1/20 0.37
KDM1A O60341 1/20 0.37
MAOA P21397 1/20 0.37
RCOR1 Q9UKL0 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11959128 0.89 PTGER1 (0.41) CCR2MEN1KMT2AP2RX4ALDH1A1
SCHEMBL2484224 0.83 LMNA (0.52) CCR2MEN1KMT2AHTTHSD17B10
SCHEMBL8818348 0.81 ALDH1A1 (0.39) CCR2KMT2AHSD17B10ALDH1A1LMNA
SCHEMBL6542176 0.79 OGT (0.51) CCR2KMT2AHTTALDH1A1OGT
SCHEMBL8819849 0.79 LMNA (0.40) CCR2KMT2AP2RX4HTTALDH1A1
SCHEMBL7166716 0.75 OXER1 (0.52) CCR2MEN1KMT2AP2RX4ALDH1A1
SCHEMBL8818368 0.75 ALDH1A1 (0.48) CCR2MEN1KMT2AHSD17B10ALDH1A1
SCHEMBL28163341 0.71 GAA (0.46) MEN1KMT2AGFERHSD17B10ALDH1A1
SCHEMBL6528127 0.71 KDM4E (0.43) P2RX4ALDH1A1LMNAL3MBTL1NPSR1
SCHEMBL6647703 0.70 ALDH1A1 (0.60) MEN1KMT2AP2RX4ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236963-B2 Tricyclic spiro derivatives as CRTH2 modulators MERCK SERONO SA (CH) 2012-08-07 US disclosed
EP-1891075-B1 TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS MERCK SERONO SA (CH) 2011-10-19 EP disclosed
US-20090318486-A1 Tricyclic spiro derivatives as CRTH2 modulators LABORATOIRES SERONO S.A. (CH) 2009-12-24 US disclosed
EP-1891075-A1 TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS LABORATOIRES SERONO S.A. (CH) 2008-02-27 EP disclosed
WO-2006125784-A1 TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS LABORATOIRES SERONO S.A. (CH) 2006-11-30 WO disclosed
WO-1997036895-A1 PROCESS FOR THE PREPARATION OF TENIDAP EGIS Gyógyszergyár Rt. (HU) 1997-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318486-A1 Tricyclic spiro derivatives as CRTH2 modulators RORB, NR3C2, NR1H2 CCR2 112/4885MEN1 4303/4885KMT2A 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.